Revealed: The growing crisis of workplace-related eye injuries
5 March 2025
|
industry, NuVision, occupational health, occupational safety, eye health, patient information
Nearly half of UK workers believe their job puts their eye health at risk, yet are businesses overlooking this critical issue? New survey findings commissioned by NuVision Biotherapies highlight a rising yet often ignored concern in workplace health; eye injuries...
ABDO announces groundbreaking therapy for contact lens opticians
1 October 2024
|
novel therapies, contact lens, ABDO, optometry, optician, research, new studies, Omnigen, Omnilenz, NuVision, Andy Hill
The Association of British Dispensing Opticians (ABDO) has given the go ahead for contact lens opticians to prescribe a groundbreaking new therapy, enabling ~1,700 new practitioners to offer the treatment to their patients. NuVision Biotherapies, a UK based tissue-therapy company...
Andy Hill (NuVision Biotherapies) discusses recent AOP update to clinical guidelines
8 December 2023
|
NuVision, Andy Hill, amniotic membranes, guidelines, AOP, optometrist, outpatient, dry eye, lens
There are currently 600,000 people on the NHS waiting list for ophthalmology treatment, and over 5 million people in the UK currently live with dry eye disease. Here Andy Hill, CEO at NuVision Biotherapies Ltd, discusses a recent update to clinical guidelines and what this means for optometrists, patients, and taxpayers.
